Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 28, 2026 | $2.84 | +15.0% | $3.04B | +10.2% | $2.81 |
| Q1 FY26ended Mar 31, 2026 | Apr 28, 2026 | $2.24 | +15.5% | $2.90B | +9.2% | $2.37 |
| Q4 FY25ended Dec 31, 2025 | — | $2.17 | +11.9% | $2.81B | +7.1% | — |
| Q3 FY25ended Sep 30, 2025 | — | $2.16 | +8.5% | $2.82B | +13.2% | — |
| Q2 FY25ended Jun 30, 2025 | — | $2.47 | +21.7% | $2.76B | +15.2% | — |
| Q1 FY25ended Mar 31, 2025 | — | $1.94 | +12.8% | $2.65B | +12.1% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.94 | +12.1% | $2.62B | +14.6% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.99 | +1.5% | $2.49B | +8.4% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Quest Diagnostics shares, not any token. As of Jul 28, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $2.03 | — | $2.40B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $1.72 | — | $2.37B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.73 | — | $2.29B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $1.96 | — | $2.30B | — | — |